Comparing Serum Interleukin 31 levels in patients of Chronic Spontaneous Urticaria and healthy controls and correlating it with the disease severity.
Not Applicable
- Conditions
- Health Condition 1: L508- Other urticaria
- Registration Number
- CTRI/2024/06/069528
- Lead Sponsor
- Dr Janice Reema Lewis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed with Chronic spontaneous Urticaria who agree to take part in the study.
2. Patients who do not have any comorbidities.
Exclusion Criteria
1. Patients with coexisting conditions which show increased levels of IL 31 like atopic dermatitis, prurigo nodularis, psoriasis, bullous pemphigoid.
2. Patients on oral corticosteroids or other immunosuppressive drugs in the last 8 weeks or antihistamines atleast 4 days before the day of assessment.
3. Patients with any acute infection, immune complex disease, other autoimmune diseases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To estimate the levels of Serum IL 31 in patients with Chronic spontaneous urticaria. <br/ ><br>2. To compare serum IL 31 levels among patients with chronic spontaneous urticaria and healthy controls. <br/ ><br>3. To determine the severity of chronic spontaneous urticaria. <br/ ><br>4. To determine the correlation of serum IL 31 levels with the severity of chronic spontaneous urticaria.Timepoint: At Baseline.
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil